AI-generated summary
This review describes the authors' work on small-molecule optical probes for amyloid beta in Alzheimer's disease, covering near-infrared fluorescent probes, chemiluminescence probes for deeper whole-brain imaging, and molecular light for therapy. The authors report that CRANAD-X probes can monitor therapeutic efficacy over time in mice and that molecular light therapy could slow amyloid accumulation in AD mice. The abstract describes these as feasibility findings.
- Who or what was studied
- Alzheimer's disease mouse models
- Limits stated in the abstract
- The abstract describes the authors' own prior research in a review-style overview, reports feasibility-level findings in mice, and provides no quantitative results or human data.
Written by an AI model from this paper’s abstract only and checked automatically against it, but it can still be wrong. It is not medical advice. Read the full paper. See the editorial policy.
Abstract
The full abstract is not shown here because it is protected by the publisher’s copyright. Read it on pubs.acs.org.
Record from PubMed, a service of the National Library of Medicine.
How to read a single study: what to check before relying on this kind of research.
Terms in this paper: Phototherapy, Photodynamic therapy, Photobiomodulation, Near-infrared. Each links to its definition in the glossary.
A summary of published research, not medical advice. One study rarely settles a question. See the disclaimer and how to read research.